Alcoholic Hepatitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Alcoholic Hepatitis - Pipeline Review, H2 2016

Alcoholic Hepatitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Alcoholic Hepatitis - Pipeline Review, H2 2016
Published Sep 14, 2016
67 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alcoholic Hepatitis - Pipeline Review, H2 2016, provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
- The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline

  
Source:
Document ID
GMDHC8461IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Alcoholic Hepatitis Overview71
Therapeutics Development82
  Pipeline Products for Alcoholic Hepatitis Overview81
  Pipeline Products for Alcoholic Hepatitis Comparative Analysis91
Alcoholic Hepatitis Therapeutics under Development by Companies101
Alcoholic Hepatitis Therapeutics under Investigation by Universities/Institutes111
Alcoholic Hepatitis Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Alcoholic Hepatitis Products under Development by Companies141
Alcoholic Hepatitis Products under Investigation by Universities/Institutes151
Alcoholic Hepatitis Companies Involved in Therapeutics Development169
  Alfact Innovation161
  Conatus Pharmaceuticals Inc.171
  Generon (Shanghai) Corporation Ltd.181
  Genextra S.p.a.191
  Gilead Sciences, Inc.201
  GRI Bio, Inc.211
  Immuron Limited221
  Promethera Biosciences S.A.231
  Verlyx Pharma Inc.241
Alcoholic Hepatitis Therapeutics Assessment259
  Assessment by Monotherapy Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type322
Drug Profiles3429
  ALF-5755 Drug Profile341
  emricasan Drug Profile356
  F-652 Drug Profile411
  GRI-0621 Drug Profile421
  HepaStem Drug Profile432
  IMM-124E Drug Profile453
  obeticholic acid Drug Profile489
  Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease Drug Profile572
  pentamidine isethionate Drug Profile592
  PMKM-02GI1 Drug Profile611
  selonsertib Drug Profile621
Alcoholic Hepatitis Dormant Projects631
Alcoholic Hepatitis Product Development Milestones642
  Featured News &Press Releases641
    Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients641
    Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population642
Appendix662
  Methodology661
  Coverage661
  Secondary Research661
  Primary Research661
  Expert Panel Validation661
  Contact Us661
  Disclaimer671

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alcoholic Hepatitis - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alcoholic-Hepatitis-Pipeline-Review-H2-2016-2088-16546>
  
APA:
Global Markets Direct - Market Research. (2016). Alcoholic Hepatitis - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alcoholic-Hepatitis-Pipeline-Review-H2-2016-2088-16546>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.